PharmaShots | Incisive News in 3 Shots

Subscribe Now

Hyperkalaemia

AstraZeneca's Lokelma Receives Fast Track Designation for the Treatment of Chronic Haemodialysis with Hyperkalaemia

AstraZeneca's Lokelma Receives Fast Track Designation for the Treatment of Chronic Haemodialysis with Hyperkalaemia

November 18, 2021

AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives NMPA's Approval for Patients with Hyperkalaemia

AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives NMPA's Approval for Patients with Hyperkalaemia

January 6, 2020

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients...

June 14, 2019

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III HARMONIZE trial in Patients with Hyperkalaemia

AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III HARMONIZE trial in Patients with Hyperkalaemia

October 26, 2018

AstraZeneca's Lokelma Receives FDA's Approval for Patients with Hyperkalaemia in Adults

AstraZeneca's Lokelma Receives FDA's Approval for Patients with Hyperkalaemia in Adults

May 18, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us